Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...

Shares of newly public Metsera (MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a $275M initial public offering. Read more here.

Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

Your favorite toys and weight-loss drugs could be priced out of reach if Donald Trump is serious. Denmark’s defiant message ...

Donald Trump has on several occasions floated the idea of buying Greenland, the autonomous Danish territory. However, there is no shortage of economic leverage for Denmark to hurt the United States.

More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug ...

The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...